A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

Bueno, Clara; Torres-Ruiz, Raul; Velasco-Hernandez, Talia; Molina, Oscar; Petazzi, Paolo; Martinez, Alba; Rodriguez, Virginia; Vinyoles, Meritxell; Cantilena, Sandra; Williams, Owen; Vega-Garcia, Nerea; Rodriguez-Perales, Sandra; Segovia, Jose C.; Quintana-Bustamante, Oscar; Roy, Anindita; Meyer, Claus; Marschalek, Rolf; Smith, Alastair L.; Milne, Thomas A.; Fraga, Mario F.; Tejedor, Juan Ramón; Menéndez, Pablo

doi:10.1182/blood.2023020858

Skip Nav Destination

Letter to Blood| November 16, 2023

A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

Clara Bueno,

Clara Bueno

1Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain

2Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain

3Spanish Collaborative Cancer Network, Carlos III Health Institute, Barcelona, Spain

https://orcid.org/0000-0003-1442-6216

Search for other works by this author on:

This Site

PubMed

Google Scholar

Raul Torres-Ruiz,

Raul Torres-Ruiz

1Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain

4Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain

5Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain

6Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain

7Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

https://orcid.org/0000-0001-9606-0398

Search for other works by this author on:

This Site

PubMed

Google Scholar

Talia Velasco-Hernandez,

Talia Velasco-Hernandez

1Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain

2Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain

https://orcid.org/0000-0003-2183-7443

Search for other works by this author on:

This Site

PubMed

Google Scholar

Oscar Molina,

Oscar Molina

1Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain

2Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain

https://orcid.org/0000-0001-7585-4519

Search for other works by this author on:

This Site

PubMed

Google Scholar

Paolo Petazzi,

Paolo Petazzi

1Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain

Search for other works by this author on:

This Site

PubMed

Google Scholar

Alba Martinez,

Alba Martinez

1Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain

2Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain

Search for other works by this author on:

This Site

PubMed

Google Scholar

Virginia Rodriguez,

Virginia Rodriguez

1Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain

2Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain

Search for other works by this author on:

This Site

PubMed

Google Scholar

Meritxell Vinyoles,

Meritxell Vinyoles

1Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain

2Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain

https://orcid.org/0000-0003-1906-4701

Search for other works by this author on:

This Site

PubMed

Google Scholar

Sandra Cantilena,

Sandra Cantilena

8Development Biology Cancer Program, Cancer Section, UCLGOS Institute of Child Health, London, United Kingdom

https://orcid.org/0000-0002-1986-7873

Search for other works by this author on:

This Site

PubMed

Google Scholar

Owen Williams,

Owen Williams

8Development Biology Cancer Program, Cancer Section, UCLGOS Institute of Child Health, London, United Kingdom

Search for other works by this author on:

This Site

PubMed

Google Scholar

Nerea Vega-Garcia,

Nerea Vega-Garcia

9Hematology Laboratory, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain

10Developmental Tumors Biology Group, Leukemia, and other Pediatric Hemopathies, Pediatric Cancer Center Barcelona, Institut de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain

https://orcid.org/0000-0002-3190-063X

Search for other works by this author on:

This Site

PubMed

Google Scholar

Sandra Rodriguez-Perales,

Sandra Rodriguez-Perales

7Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

https://orcid.org/0000-0001-7221-3636

Search for other works by this author on:

This Site

PubMed

Google Scholar

Jose C. Segovia,

Jose C. Segovia

4Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain

5Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain

6Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain

https://orcid.org/0000-0003-4101-6124

Search for other works by this author on:

This Site

PubMed

Google Scholar

Oscar Quintana-Bustamante,

Oscar Quintana-Bustamante

4Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain

5Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain

6Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain

https://orcid.org/0000-0002-6869-7006

Search for other works by this author on:

This Site

PubMed

Google Scholar

Anindita Roy,

Anindita Roy

11MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

12Department of Pediatrics and National Institute for Health and Care Research Oxford Biomedical Research Centre Hematology Theme, University of Oxford, Oxford, United Kingdom

Search for other works by this author on:

This Site

PubMed

Google Scholar

Claus Meyer,

Claus Meyer

13Diagnostic Center of Acute Leukemia–Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany

Search for other works by this author on:

This Site

PubMed

Google Scholar

Rolf Marschalek,

Rolf Marschalek

13Diagnostic Center of Acute Leukemia–Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany

https://orcid.org/0000-0003-4870-3445

Search for other works by this author on:

This Site

PubMed

Google Scholar

Alastair L. Smith,

Alastair L. Smith

https://orcid.org/0000-0001-6330-1407

Search for other works by this author on:

This Site

PubMed

Google Scholar

Thomas A. Milne,

Thomas A. Milne

https://orcid.org/0000-0002-0413-4271

Search for other works by this author on:

This Site

PubMed

Google Scholar

Mario F. Fraga,

Mario F. Fraga

6Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain

14Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center, El Entrego, Spain

15Health Research Institute of Asturias, Institute of Oncology of Asturias and Department of Organisms and Systems Biology, University of Oviedo, Oviedo, Spain

https://orcid.org/0000-0001-8450-2603

Search for other works by this author on:

This Site

PubMed

Google Scholar

Juan Ramón Tejedor,

Juan Ramón Tejedor

6Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain

14Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center, El Entrego, Spain

15Health Research Institute of Asturias, Institute of Oncology of Asturias and Department of Organisms and Systems Biology, University of Oviedo, Oviedo, Spain

https://orcid.org/0000-0002-4061-9698

Search for other works by this author on:

This Site

PubMed

Google Scholar

Pablo Menéndez

1Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain

2Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain

3Spanish Collaborative Cancer Network, Carlos III Health Institute, Barcelona, Spain

16Department of Biomedicine, University of Barcelona, Barcelona, Spain

17Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain

https://orcid.org/0000-0001-9372-1007

Search for other works by this author on:

This Site

PubMed

Google Scholar

Blood (2023) 142 (20): 1752–1756.

https://doi.org/10.1182/blood.2023020858

Article history

Submitted:

April 18, 2023

Accepted:

August 18, 2023

First Edition:

September 26, 2023

Share
- Facebook
- Twitter
- LinkedIn
- Email
Tools
- Request Permissions
- Cite
Search Site

Citation

Clara Bueno, Raul Torres-Ruiz, Talia Velasco-Hernandez, Oscar Molina, Paolo Petazzi, Alba Martinez, Virginia Rodriguez, Meritxell Vinyoles, Sandra Cantilena, Owen Williams, Nerea Vega-Garcia, Sandra Rodriguez-Perales, Jose C. Segovia, Oscar Quintana-Bustamante, Anindita Roy, Claus Meyer, Rolf Marschalek, Alastair L. Smith, Thomas A. Milne, Mario F. Fraga, Juan Ramón Tejedor, Pablo Menéndez; A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features. Blood 2023; 142 (20): 1752–1756. doi: https://doi.org/10.1182/blood.2023020858

Download citation file:

Ris (Zotero)
Reference Manager
EasyBib
Bookends
Mendeley
Papers
EndNote
RefWorks
BibTex

toolbar search

search input Search input auto suggest

filter your search

Abstract

Cellular ontogeny and MLL breakpoint site influence the capacity of MLL-edited CD34⁺ hematopoietic cells to initiate and recapitulate infant patients' features in pro–B-cell acute lymphoblastic leukemia (B-ALL). We provide key insights into the leukemogenic determinants of MLL-AF4⁺ infant B-ALL.

Subjects:

Lymphoid Neoplasia

References

Sanjuan-Pla

Bueno

Prieto

, et al.

Revisiting the biology of infant t(4;11)/MLL-AF4⁺ B-cell acute lymphoblastic leukemia

Blood

2015

;

126

(

2676

2685

Meyer

Burmeister

Groger

, et al.

The MLL recombinome of acute leukemias in 2017

Leukemia

2018

;

(

273

284

Agraz-Doblas

Bueno

Bashford-Rogers

, et al.

Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis

Haematologica

2019

;

104

(

1176

1188

Andersson

Wang

, et al.

The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias

Nat Genet

2015

;

(

330

337

Pui

Campana

Age-related differences in leukemia biology and prognosis: the paradigm of MLL-AF4-positive acute lymphoblastic leukemia

Leukemia

2007

;

(

593

594

Jung

Jacobs

Krumbholz

, et al.

Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment

Leukemia

2010

;

(

903

907

Reichel

Gillert

Angermuller

, et al.

Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL

Oncogene

2001

;

(

2900

2907

Symeonidou

Ottersbach

HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia

Exp Hematol

2021

;

43.e5

Prieto

Stam

Agraz-Doblas

, et al.

Activated KRAS cooperates with MLL-AF4 to promote extramedullary engraftment and migration of cord blood CD34+ HSPC but is insufficient to initiate leukemia

Cancer Res

2016

;

(

2478

2489

10.

Lin

Luo

Ptasinska

, et al.

Instructive role of MLL-fusion proteins revealed by a model of t(4;11) pro-B acute lymphoblastic leukemia

Cancer Cell

2016

;

(

737

749

11.

Bueno

Tejedor

Bashford-Rogers

, et al.

Natural history and cell of origin of TC F3-ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL

Blood

2019

;

134

(

900

905

12.

Montes

Ayllon

Prieto

, et al.

Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells

Leukemia

2014

;

(

666

674

13.

Rice

Jackson

Crump

, et al.

A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program

Nat Commun

2021

;

(

6905

14.

Secker

Bruns

Keppeler

, et al.

Only hematopoietic stem and progenitor cells from cord blood are susceptible to malignant transformation by MLL-AF4 translocations

Cancers (Basel)

2020

;

(

1487

15.

Kuhn

Loscher

Marschalek

The IRX1/HOXA connection: insights into a novel t(4;11)- specific cancer mechanism

Oncotarget

2016

;

(

35341

35352

16.

Stam

Schneider

Hagelstein

, et al.

Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants

Blood

2010

;

115

(

2835

2844

17.

Trentin

Giordan

Dingermann

Basso

Te Kronnie

Marschalek

Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients

Eur J Haematol

2009

;

(

406

419

18.

Meyer

Larghero

Almeida Lopes

, et al.

The KMT2A recombinome of acute leukemias in 2023

Leukemia

2023

;

(

988

1005

19.

Kulp

Siemund

Larghero

, et al.

The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia

iScience

2022

;

(

104613

20.

Zeisig

Milne

Garcia-Cuellar

, et al.

Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization

Mol Cell Biol

2004

;

(

617

628

21.

Tirtakusuma

Szoltysek

Milne

, et al.

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

Blood

2022

;

140

(

1875

1890

2023

You do not currently have access to this content.

Submit a comment

Name Please enter your name.

Affiliations Please enter your affiliations

Comment title Please supply a title for your comment.

Comment This field is required

I agree to the terms and conditions. You must accept the terms and conditions.

Read the terms and conditions

You have entered an invalid code.

Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.

Comment not saved. Please try again.

This feature is available to Subscribers Only

My Account

24-Hour Access

$100.00

Purchase This Article

Volume 142, Issue 20

November 16 2023

Advertisement intended for health care professionals

1 Web of Science

View Metrics

Cited By

Web Of Science (1)

Google Scholar

Email alerts

Article Activity Alert

First Edition Alert

Latest Issue Alert

Advertisement intended for health care professionals

A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

Abstract

References

24-Hour Access

Cited By

Email alerts

ASH Publications

American Society of Hematology

A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

Abstract

References

This feature is available to Subscribers Only

My Account

My Account

24-Hour Access

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only